NCT04340245Active, not recruiting
Exploiting Risk-Based Risk Stratification in Early Prostate Cancer to Discriminate Progressors From Non-Progressors
Source: ClinicalTrials.gov · Last updated 26 Feb 2024
Brief summary (registry, in English)
This study seeks to analyse MRI images and biological samples from 60 men diagnosed as having intermediate risk prostate cancer at baseline and one year afterwards to compare the molecular, genetic and transcriptomic differences between cancers that progress and cancers which do not.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 21 Jan 2020
- Start date
- 1 Jul 2020
- Primary completion date
- 30 Mar 2024
- Lead sponsor
- University College, London
- Diseases
- Prostate cancer
- NCT number
- NCT04340245
What you commit to
- Study type: Observational
- Planned participants: 60
- From 1 Jul 2020 to the primary completion date, 30 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any contraindication to MRI scans (e.g. metal implants, unmanageable claustrophobia)
- Any hormonal treatment or inhibitors of 5 alpha-reductase in the previous 6 months
- Any previous TURP or other prostate surgery.
- Previous treatment for prostate cancer.
- Patients who have previously had sepsis due to a prostate biopsy
- Patients receiving concomitant treatment for their cancer
Other illness
- Inability to provide full informed consent (e.g. due to dementia)
Other
- Presence of a pacemaker
- Presence of a hip replacement
Who the study is looking for
- Male aged 18 years or above.
- Diagnosed with prostate cancer within 4 months of entry.
- Likert or PIRADS score greater than or equal to 4.
- PSA less than or equal to 15 ng.ml-1 in the last 6 months.
- mpMRI concordant with histology.
- Overall Gleason score 7 (3+4).
- Maximum cancer core length less than or equal to 10mm.
- Patients on active surveillance
Age in the registry: 18 years to - · Sex: Male
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University College Hospital Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.